BioCryst Pharmaceuticals
BCRX
#5073
Rank
โ‚น143.56 B
Marketcap
โ‚น681.86
Share price
-3.07%
Change (1 day)
5.81%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of September 2025 : โ‚น57.98 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is โ‚น57.98 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚น69.37 B1%
2023-12-31โ‚น68.69 B11.96%
2022-12-31โ‚น61.35 B38.95%
2021-12-31โ‚น44.15 B116.01%
2020-12-31โ‚น20.44 B238.61%
2019-12-31โ‚น6.03 B39.65%
2018-12-31โ‚น4.32 B23.72%
2017-12-31โ‚น3.49 B-4.29%
2016-12-31โ‚น3.65 B82.04%
2015-12-31โ‚น2.00 B5.48%
2014-12-31โ‚น1.90 B2.59%
2013-12-31โ‚น1.85 B12.83%
2012-12-31โ‚น1.64 B3.5%
2011-12-31โ‚น1.58 B
2000-12-31โ‚น0.45 M
1997-12-31โ‚น3.92 M-63.56%
1996-12-31โ‚น10.78 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
โ‚น61.88 B 6.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น112.31 B 93.70%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
โ‚น0.13 B-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚น22.56 B-61.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
โ‚น2.240 T 3,764.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚น0.23 B-99.59%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚น2.143 T 3,597.11%๐Ÿ‡ฌ๐Ÿ‡ง UK
Emergent BioSolutions
EBS
โ‚น59.57 B 2.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
โ‚น0.89 B-98.46%๐Ÿ‡บ๐Ÿ‡ธ USA